ReachMD

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Vizitează neapărat site-ul podcastului și susține-i creatorul: reachmd.com

Autor

ReachMD

Categorie

Science

Site-ul podcastului

reachmd.com

Cel mai nou episod

20 oct. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

Beyond the Scalpel: When TGCT Surgery Isn’t the Solution 15.12.2025

CME credits: 1.00 Valid until: 15-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-scalpel-when-tgct-surgery-isnt-the-solution/48904/ This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight cli...

The Tumor That’s Not So Tiny: Understanding the Impact of TGCT 15.12.2025

CME credits: 1.00 Valid until: 15-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-tumor-thats-not-so-tiny-understanding-the-impact-of-tgct/39305/ This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlig...

Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis 15.12.2025

CME credits: 0.50 Valid until: 15-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-the-latest-diagnostic-and-treatment-approaches-for-generalized-myasthenia-gravis/32961/ In this expert commentary, Dr. Narayanaswami highlights key messages from the Prova Education satellite symposium held at the 2025 AANEM Meeting in San Francisco. The discussion centers on the clinic...

Advances in the Treatment of Overt Hepatic Encephalopathy: What's in the Pipeline? 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-oreatment-of-overt-hepatic-encephalopathy-whats-in-the-pipeline/39794/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE...

Current Treatment of Hepatic Encephalopathy: Is It Meeting Our Patients' Needs? 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Current-Treatment-of-Hepatic-Encephalopathy-Is-It-Meeting-Our-Patients-Needs/39793/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE an...

Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Optimizing-Care-of-the-Hospitalized-Patient-With-Overt-Hepatic-Encephalopathy/39792/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE a...

Treatment of Hepatic Encephalopathy: Primary vs Secondary Prophylaxis 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Treatment-of-Hepatic-Encephalopathy-Primary-vs-Secondary-Prophylaxis/39791/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer...

Treatment of Hepatic Encephalopathy: When, What, How, and Why? 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Treatment-of-Hepatic-Encephalopathy-When-What-How-and-Why/39790/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies...

The Slippery Slope of Overt Hepatic Encephalopathy 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/The-Slippery-Slope-of-Overt-Hepatic-Encephalopathy/39789/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for tim...

Minimal Hepatic Encephalopathy: A Covert Operation? 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Minimal-Hepatic-Encephalopathy-A-Covert-Operation/39788/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for time...

Minimal Hepatic Encephalopathy: Hiding in Plain Sight? 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Minimal-Hepatic-Encephalopathy-Hiding-in-Plain-Sight/39787/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for t...

Hepatic Encephalopathy: More Common Than You Think 11.12.2025

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/ T his series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for time...

Advances in Treatment of Hypoparathyroidism: Importance of Genetic Testing for Autosomal Dominant Hypocalcemia Type 1 10.12.2025

CME credits: 0.50 Valid until: 10-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-treatment-of-hypoparathyroidism-importance-of-genetic-testing-for-autosomal-dominant-hypocalcemia-type-1/36097/ This CME activity focuses on enhancing clinician recognition and management of autosomal dominant hypocalcemia type 1 (ADH1). Learners will explore the pathophysiology and clin...

Taking Action Against RSV: No Child Unprotected 04.12.2025

CME credits: 0.50 Valid until: 04-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/taking-action-against-rsv-no-child-unprotected/39307/ This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylac...

Early Action in Obesity: Transforming Practice, Improving Outcomes 03.12.2025

CME credits: 0.25 Valid until: 03-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/early-action-in-obesity-transforming-practice-improving-outcomes/36273/ Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landsca...

Future mCRC Directions: Enhancing Anti-EGFR Therapy With Novel Combination Strategies 02.12.2025

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-mcrc-directions-enhancing-anti-egfr-therapy-with-novel-combination-strategies/48870/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mut...

Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life 02.12.2025

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-proofing-in-hae-advances-in-long-term-prophylaxis-to-prevent-attacks-and-improve-quality-of-life/54448/ On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patie...

Rethinking Schizophrenia Treatment Through Muscarinic Modulation 02.12.2025

CME credits: 0.25 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/ In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side...

A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies 26.11.2025

CME credits: 0.25 Valid until: 26-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/ Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact pa...

IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies 19.11.2025

CME credits: 0.25 Valid until: 19-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/ Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria...

Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40% 18.11.2025

CME credits: 0.25 Valid until: 18-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/ Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and...

Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms 14.11.2025

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/looking-ahead-integrating-cdh6-targeted-therapies-into-ovarian-cancer-treatment-paradigms/37866/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targ...

Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates 14.11.2025

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conju...

Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies 14.11.2025

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug...

MOA: CDH6-Targeted Antibody-Drug Conjugates 14.11.2025

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent...

Ascultă podcastul ReachMD CME în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice